Entrada Therapeutics Inc (TRDA)
14.30
+0.05
(+0.35%)
USD |
NASDAQ |
Jul 01, 16:00
14.30
0.00 (0.00%)
After-Hours: 20:00
Entrada Therapeutics Cash from Financing (Quarterly): 0.206M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.206M |
| December 31, 2023 | 0.69M |
| September 30, 2023 | 0.368M |
| June 30, 2023 | 0.443M |
| March 31, 2023 | 19.54M |
| December 31, 2022 | 0.358M |
| September 30, 2022 | 0.06M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.011M |
| March 31, 2022 | 0.05M |
| December 31, 2021 | 190.76M |
| September 30, 2021 | 0.106M |
| June 30, 2021 | 0.215M |
| March 31, 2021 | 116.38M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.011M
Minimum
Jun 2022
190.76M
Maximum
Dec 2021
25.32M
Average
0.358M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 141.05M |
| Vertex Pharmaceuticals Inc | -357.50M |
| Sarepta Therapeutics Inc | 22.14M |
| PTC Therapeutics Inc | 0.54M |
| GlycoMimetics Inc | 0.0049M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -25.52M |
| Cash from Investing (Quarterly) | 26.15M |
| Free Cash Flow | -93.90M |
| Free Cash Flow Per Share (Quarterly) | -0.7576 |
| Free Cash Flow to Equity (Quarterly) | -26.36M |
| Free Cash Flow to Firm (Quarterly) | -26.36M |
| Free Cash Flow Yield | -19.30% |